Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-01-14 DOI:10.1002/hon.70038

Veronica Guglielmana, Francesco Maria Fusi, Valentina Giardini, Federica Cocito, Carlo Gambacorti-Passerini

引用次数: 0

Abstract

Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcomes, but its management in patients desiring parenthood remains an issue. This study presents the first description of four successful pregnancies during crizotinib treatment for ALK+ALCL: a female patient achieving two pregnancies through assisted reproductive technologies (ART), temporarily discontinuing crizotinib and maintaining a complete remission (CR), and a male patient conceiving naturally while on continuous therapy. These cases demonstrate crizotinib potential to support conception without compromising disease control, even in the absence of specific guidelines on treatment discontinuation.

查看原文本刊更多论文

克唑替尼治疗间变性淋巴瘤激酶阳性淋巴瘤期间妊娠成功。

间变性淋巴瘤激酶阳性（ALK+）间变性大细胞淋巴瘤（ALCL）通常发生在年轻人身上，尽管对细胞毒性药物有很高的反应性，但超过50%的患者会复发。克唑替尼改善了治疗效果，但对渴望生育的患者的治疗仍是一个问题。本研究首次描述了在克唑替尼治疗ALK+ALCL期间成功怀孕的四例：一名女性患者通过辅助生殖技术（ART）实现两次怀孕，暂时停用克唑替尼并保持完全缓解（CR），一名男性患者在持续治疗期间自然受孕。这些病例表明，即使在没有关于停止治疗的具体指南的情况下，克唑替尼也有可能在不影响疾病控制的情况下支持受孕。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.